Unmet Needs In CLL and SLL Treatment Management

EP: 1.Clinical Characteristics Distinguishing CLL and SLL

EP: 2.Quality of Life Impacted By CLL and SLL Diagnosis and Management

EP: 3.Evaluating Current Treatment Landscape of CLL and SLL

Now Viewing

EP: 4.Unmet Needs In CLL and SLL Treatment Management

EP: 5.Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management

EP: 6.Examining Safety and Efficacy of BTK Inhibitors In CLL and SLL Treatment

EP: 7.Determining Optimal CLL / SLL Therapy: Ibrutinib, Acalabrutinib and Zanubrutinib

EP: 8.Key Highlights From ASH 2023

EP: 9.Economic Burden Associated With BTK Inhibitor Use

EP: 10.Patient Education Driving BTK Inhibitor Treatment Adherence

EP: 11.Optimizing BTKi Treatment Strategies

EP: 12.Key Considerations for Treating Patients Diagnosed With CLL and SLL

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; and Jennifer Woyach, MD.

Stephens discusses how Bruton tyrosine kinase (BTK) inhibitors address unmet needs in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) compared to previouschemotherapies with severe adverseeffects that impacted patients’ lives. Ibrutinib was a game changer as the first BTK inhibitor that patients could take as a pill at home. This ease of access and high efficacy servesa major unmet need. Even newer therapies still require in-person infusions unlike BTK inhibitors, which can be shipped to patients directly. This provides wider access with less frequent lab monitoring or clinic visits.

However, unmet needs remain since these drugs are not curative and must be taken continuously. Adverseeffects still occur, and resistance can develop after multiple lines of therapy. So while BTK inhibitors have helped patients live their liveswith minimal impact, areas needing work include finding a cure, further reducing adverseeffects, and overcoming resistance. A key benefit is the convenience and accessibility for patients.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.